{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:04:46Z","timestamp":1789571086295,"version":"build-2803163510"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10379-2","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:31:48Z","timestamp":1789569108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Castration-resistant prostate cancer as an adaptive tumor ecosystem: coupling tumor evolution with microenvironmental reprogramming"],"prefix":"10.1007","volume":"45","author":[{"given":"Siliang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuwen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"1","key":"10379_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","volume":"36","author":"DE Rathkopf","year":"2025","unstructured":"Rathkopf, D. E., et al. (2025). Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology, 36(1), 76\u201388. https:\/\/doi.org\/10.1016\/j.annonc.2024.09.005","journal-title":"Annals of Oncology"},{"key":"10379_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Zhou, Q., Hankey, W., Fang, X., & Yuan, F. (2022). Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death & Disease, 13. https:\/\/doi.org\/10.1038\/s41419-022-05084-1","journal-title":"Cell Death & Disease"},{"key":"10379_CR3","doi-asserted-by":"publisher","unstructured":"Li, X., et al. (2026). AR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating FDX1. Proceedings of the National Academy of Sciences, 123, e2534978123. https:\/\/doi.org\/10.1073\/pnas.2534978123","DOI":"10.1073\/pnas.2534978123"},{"key":"10379_CR4","doi-asserted-by":"publisher","unstructured":"Woodcock, D. J., et al. (2020). Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. Nature Communications, 11, 5070.  https:\/\/doi.org\/10.1038\/s41467-020-18843-5","DOI":"10.1038\/s41467-020-18843-5"},{"key":"10379_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481, 306\u2013313. https:\/\/doi.org\/10.1038\/nature10762","journal-title":"Nature"},{"key":"10379_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1158\/0008-5472.CAN-17-1924","volume":"78","author":"AM Horning","year":"2018","unstructured":"Horning, A. M., et al. (2018). Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle\u2013Related Transcription and Attenuated Androgen Response. Cancer Research, 78, 853\u2013864. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1924","journal-title":"Cancer Research"},{"key":"10379_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25624-1","volume":"12","author":"S Taavitsainen","year":"2021","unstructured":"Taavitsainen, S., et al. (2021). Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nature Communications, 12,. https:\/\/doi.org\/10.1038\/s41467-021-25624-1","journal-title":"Nature Communications"},{"key":"10379_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jpp\/rgaf100","volume":"78","author":"M Howells","year":"2025","unstructured":"Howells, M., et al. (2025). Characterizing resistance in prostate cancer at a single cell level with hormonal treatment and epigenetic inhibitors. Journal of Pharmacy and Pharmacology, 78. https:\/\/doi.org\/10.1093\/jpp\/rgaf100","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"10379_CR9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan, J. M., et al. (2022). Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science, 377, 1180\u20131191. https:\/\/doi.org\/10.1126\/science.abn0478","journal-title":"Science"},{"key":"10379_CR10","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1101\/gad.1965810","volume":"24","author":"MM Shen","year":"2010","unstructured":"Shen, M. M., & Abate-Shen, C. (2010). Molecular genetics of prostate cancer: New prospects for old challenges. Genes & Development, 24, 1967\u20132000. https:\/\/doi.org\/10.1101\/gad.1965810","journal-title":"Genes & Development"},{"key":"10379_CR11","doi-asserted-by":"publisher","unstructured":"DeMarzo, A. M., Nelson, W. G., Isaacs, W. B., & Epstein, J. I. (2003). Pathological and molecular aspects of prostate cancer. The Lancet, 361, 955\u2013964. https:\/\/doi.org\/10.1016\/S0140-6736(03)12779-1","DOI":"10.1016\/S0140-6736(03)12779-1"},{"key":"10379_CR12","doi-asserted-by":"publisher","unstructured":"Henry, G. H., et al. (2018). A cellular anatomy of the normal adult human prostate and prostatic urethra. Cell Reports, 25, 3530\u20133542.e3535. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.086","DOI":"10.1016\/j.celrep.2018.11.086"},{"key":"10379_CR13","doi-asserted-by":"publisher","unstructured":"Kiviaho, A., et al. (2024). Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nature Communications, 15, 9949. https:\/\/doi.org\/10.1038\/s41467-024-54364-1","DOI":"10.1038\/s41467-024-54364-1"},{"key":"10379_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51450-2","volume":"15","author":"MK Graham","year":"2024","unstructured":"Graham, M. K., et al. (2024). Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. Nature Communications, 15. https:\/\/doi.org\/10.1038\/s41467-024-51450-2","journal-title":"Nature Communications"},{"key":"10379_CR15","doi-asserted-by":"publisher","unstructured":"Bian, X., et al. (2024). Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 11, 2305724. https:\/\/doi.org\/10.1002\/advs.202305724","DOI":"10.1002\/advs.202305724"},{"key":"10379_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27322-4","volume":"13","author":"H Song","year":"2022","unstructured":"Song, H., et al. (2022). Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nature Communications, 13. https:\/\/doi.org\/10.1038\/s41467-021-27322-4","journal-title":"Nature Communications"},{"key":"10379_CR17","doi-asserted-by":"publisher","unstructured":"Huang, F., et al. (2026). Programmable mRNA 3\u2032UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer. Nature Biomedical Engineering.  https:\/\/doi.org\/10.1038\/s41551-026-01720-9","DOI":"10.1038\/s41551-026-01720-9"},{"key":"10379_CR18","doi-asserted-by":"publisher","unstructured":"Calcinotto, A., et al. (2018). IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature, 559, 363\u2013369. https:\/\/doi.org\/10.1038\/s41586-018-0266-0","DOI":"10.1038\/s41586-018-0266-0"},{"key":"10379_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202510602","volume":"12","author":"W Wang","year":"2025","unstructured":"Wang, W., et al. (2025). Enzalutamide-resistant STEAP4+ MyoCAF secrete phosphatidylcholine to foster progression by activating stemness in hormone-sensitive prostate cancer. Advanced Science, 12. https:\/\/doi.org\/10.1002\/advs.202510602","journal-title":"Advanced Science"},{"key":"10379_CR20","doi-asserted-by":"publisher","unstructured":"Peng, S., et al. (2022). Single-cell analysis reveals EP4 as a target for restoring T-Cell infiltration and sensitizing prostate cancer to immunotherapy. Clinical Cancer Research, 28, 552\u2013567. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0299","DOI":"10.1158\/1078-0432.CCR-21-0299"},{"key":"10379_CR21","doi-asserted-by":"publisher","unstructured":"Xu, H., et al. (2025). Targeting RBP4&#x2013;STRA6 retinol signaling disrupts adipose&#x2013;prostate crosstalk: A novel strategy to suppress basal cell plasticity in androgen deprivation. Metabolism - Clinical and Experimental, 169. https:\/\/doi.org\/10.1016\/j.metabol.2025.156288","DOI":"10.1016\/j.metabol.2025.156288"},{"key":"10379_CR22","doi-asserted-by":"publisher","unstructured":"Magnon, C., et al. (2013). Autonomic nerve development contributes to prostate cancer progression. Science, 341, 1236361. https:\/\/doi.org\/10.1126\/science.1236361","DOI":"10.1126\/science.1236361"},{"key":"10379_CR23","doi-asserted-by":"publisher","unstructured":"Jiang, J., et al. (2025). LHX2 rewires the metabolic and epigenetic landscape to drive tumor progression in prostate cancer. Cancer Research, 85, 4751\u20134768. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0587","DOI":"10.1158\/0008-5472.CAN-25-0587"},{"key":"10379_CR24","doi-asserted-by":"publisher","unstructured":"Li, X., et al. (2023). Spermine is a natural suppressor of AR signaling in castration-resistant prostate cancer. Cell Reports, 42, 112798. https:\/\/doi.org\/10.1016\/j.celrep.2023.112798","DOI":"10.1016\/j.celrep.2023.112798"},{"key":"10379_CR25","doi-asserted-by":"publisher","unstructured":"Yumoto, K., et al. (2016). Axl is required for TGF-\u03b22-induced dormancy of prostate cancer cells in the bone marrow. Scientific Reports, 6, 36520. https:\/\/doi.org\/10.1038\/srep36520","DOI":"10.1038\/srep36520"},{"key":"10379_CR26","doi-asserted-by":"publisher","unstructured":"Yu-Lee, L.-Y., et al. (2018). Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGF\u03b2RIII\u2013p38MAPK\u2013pS249\/T252RB pathway. Cancer Research, 78, 2911\u20132924. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1051","DOI":"10.1158\/0008-5472.CAN-17-1051"},{"key":"10379_CR27","doi-asserted-by":"publisher","unstructured":"Ren, D., et al. (2018). Wnt5a induces and maintains prostate cancer cells dormancy in bone. Journal of Experimental Medicine, 216, 428\u2013449. https:\/\/doi.org\/10.1084\/jem.20180661","DOI":"10.1084\/jem.20180661"},{"key":"10379_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7150\/ijbs.77495","volume":"19","author":"A-C Chang","year":"2023","unstructured":"Chang, A.-C., et al. (2023). The ADAM9\/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis. International Journal of Biological Sciences, 19, 760\u2013771. https:\/\/doi.org\/10.7150\/ijbs.77495","journal-title":"International Journal of Biological Sciences"},{"key":"10379_CR29","doi-asserted-by":"publisher","unstructured":"Chang, A.-C., et al. (2018). Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1\/integrin \u03b14\u03b21 system. Cancer Letters, 426, 47\u201356. https:\/\/doi.org\/10.1016\/j.canlet.2018.03.050","DOI":"10.1016\/j.canlet.2018.03.050"},{"key":"10379_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02855-5","volume":"12","author":"T Yang","year":"2026","unstructured":"Yang, T., et al. (2026). Exosome-transmitted long noncoding RNA SNHG1 promotes prostate cancer bone metastasis via YBX1\/MMP16 axis. Cell Death Discovery, 12. https:\/\/doi.org\/10.1038\/s41420-025-02855-5","journal-title":"Cell Death Discovery"},{"key":"10379_CR31","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1073\/pnas.1717363115","volume":"115","author":"K Hashimoto","year":"2018","unstructured":"Hashimoto, K., et al. (2018). Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proceedings of the National Academy of Sciences of the United States of America, 115, 2204\u20132209. https:\/\/doi.org\/10.1073\/pnas.1717363115","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10379_CR32","doi-asserted-by":"publisher","unstructured":"Lin, G., et al. (2024). IL-17RA\/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth. Oncogene, 43, 3598\u20133616. https:\/\/doi.org\/10.1038\/s41388-024-03169-z","DOI":"10.1038\/s41388-024-03169-z"},{"key":"10379_CR33","doi-asserted-by":"publisher","unstructured":"Pernigoni, N., et al. (2021). Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science, 374, 216\u2013224. https:\/\/doi.org\/10.1126\/science.abf8403","DOI":"10.1126\/science.abf8403"},{"key":"10379_CR34","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/s41388-024-03073-6","volume":"43","author":"G Lin","year":"2024","unstructured":"Lin, G., et al. (2024). Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: A comprehensive study using sequencing and animal models. Oncogene, 43, 2373\u20132388. https:\/\/doi.org\/10.1038\/s41388-024-03073-6","journal-title":"Oncogene"},{"key":"10379_CR35","doi-asserted-by":"publisher","unstructured":"Karthaus, W. R., et al. (2020). Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science, 368, 497\u2013505. https:\/\/doi.org\/10.1126\/science.aay0267","DOI":"10.1126\/science.aay0267"},{"key":"10379_CR36","doi-asserted-by":"publisher","unstructured":"Hu, J., et al. (2025).  Spatially resolved transcriptomic analysis of the adult human prostate. Nature Genetics, 57, 922\u2013933. https:\/\/doi.org\/10.1038\/s41588-025-02139-9","DOI":"10.1038\/s41588-025-02139-9"},{"key":"10379_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-025-03771-8","volume":"26","author":"M Hemberg","year":"2025","unstructured":"Hemberg, M., et al. (2025). Insights, opportunities, and challenges provided by large cell atlases. Genome Biology, 26. https:\/\/doi.org\/10.1186\/s13059-025-03771-8","journal-title":"Genome Biology"},{"key":"10379_CR38","doi-asserted-by":"publisher","unstructured":"Vandereyken, K., Sifrim, A., Thienpont, B. & Voet, T. (2023) Methods and applications for single-cell and spatial multi-omics. Nature Reviews Genetics, 24, 494\u2013515. https:\/\/doi.org\/10.1038\/s41576-023-00580-2","DOI":"10.1038\/s41576-023-00580-2"},{"key":"10379_CR39","doi-asserted-by":"publisher","unstructured":"Kharchenko, P. V. (2021). The triumphs and limitations of computational methods for scRNA-seq. Nature Methods, 18, 723\u2013732. https:\/\/doi.org\/10.1038\/s41592-021-01171-x","DOI":"10.1038\/s41592-021-01171-x"},{"key":"10379_CR40","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s43587-025-00842-0","volume":"5","author":"Y Cheng","year":"2025","unstructured":"Cheng, Y., et al. (2025). Single-cell and spatial RNA sequencing identify divergent microenvironments and progression signatures in early- versus late-onset prostate cancer. Nature Aging, 5, 909\u2013928. https:\/\/doi.org\/10.1038\/s43587-025-00842-0","journal-title":"Nature Aging"},{"key":"10379_CR41","doi-asserted-by":"publisher","unstructured":"De Vargas Roditi, L., et al. (2022). Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. Cell Reports Medicine, 3, 100604. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100604","DOI":"10.1016\/j.xcrm.2022.100604"},{"key":"10379_CR42","doi-asserted-by":"publisher","unstructured":"Chen, S., et al. (2021). Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nature Cell Biology, 23, 87\u201398. https:\/\/doi.org\/10.1038\/s41556-020-00613-6","DOI":"10.1038\/s41556-020-00613-6"},{"key":"10379_CR43","doi-asserted-by":"publisher","unstructured":"Wang, X., et al. (2009). A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature, 461, 495\u2013500. https:\/\/doi.org\/10.1038\/nature08361","DOI":"10.1038\/nature08361"},{"key":"10379_CR44","doi-asserted-by":"publisher","unstructured":"Choi, N., Zhang, B., Zhang, L., Ittmann, M. & Xin, L. (2012). Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell, 21, 253\u2013265. https:\/\/doi.org\/10.1016\/j.ccr.2012.01.005","DOI":"10.1016\/j.ccr.2012.01.005"},{"key":"10379_CR45","doi-asserted-by":"publisher","unstructured":"Mansur, M. B., et al. (2023). Evolutionary determinants of curability in cancer. Nature Ecology & Evolution, 7, 1761\u20131770. https:\/\/doi.org\/10.1038\/s41559-023-02159-w","DOI":"10.1038\/s41559-023-02159-w"},{"key":"10379_CR46","doi-asserted-by":"publisher","unstructured":"Gao, D., et al. (2024). Acetate utilization promotes hormone therapy resistance in prostate cancer through neuroendocrine differentiation. Drug Resistance Updates, 77, 101158. https:\/\/doi.org\/10.1016\/j.drup.2024.101158","DOI":"10.1016\/j.drup.2024.101158"},{"key":"10379_CR47","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","volume":"81","author":"Q Cheng","year":"2022","unstructured":"Cheng, Q., et al. (2022). Pre-existing castration-resistant prostate cancer\u2013like cells in primary prostate cancer promote resistance to hormonal therapy. European Urology, 81, 446\u2013455. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.039","journal-title":"European Urology"},{"key":"10379_CR48","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.stem.2024.05.008","volume":"31","author":"JS Kirk","year":"2024","unstructured":"Kirk, J. S., et al. (2024). Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. Cell Stem Cell, 31, 1203-1221.e1207. https:\/\/doi.org\/10.1016\/j.stem.2024.05.008","journal-title":"Cell Stem Cell"},{"key":"10379_CR49","doi-asserted-by":"publisher","unstructured":"Li, F., et al. LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer. Cell Research, 35, 59\u201371 (2025). https:\/\/doi.org\/10.1038\/s41422-024-01025-z","DOI":"10.1038\/s41422-024-01025-z"},{"key":"10379_CR50","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","volume":"3","author":"SG Zhao","year":"2017","unstructured":"Zhao, S. G., et al. (2017). Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncology, 3, 1663\u20131672. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0751","journal-title":"JAMA Oncology"},{"key":"10379_CR51","doi-asserted-by":"publisher","unstructured":"Alcon-Rodriguez, S., et al. (2025). TXNIP upregulation controls metabolism and cell cycle during androgen deprivation therapy in prostate cancer. Cell Death & Disease, 16, 817. https:\/\/doi.org\/10.1038\/s41419-025-08128-4","DOI":"10.1038\/s41419-025-08128-4"},{"key":"10379_CR52","doi-asserted-by":"publisher","unstructured":"Tang, G., et al. (2025). Luminal stem-like cells in high-risk\/locally advanced prostate cancer promote resistance to hormonal therapy. Theranostics, 15, 9558\u20139579. https:\/\/doi.org\/10.7150\/thno.112496","DOI":"10.7150\/thno.112496"},{"key":"10379_CR53","doi-asserted-by":"publisher","unstructured":"Handle, F., et al. (2019) Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Scientific Reports, 9, 13786. https:\/\/doi.org\/10.1038\/s41598-019-50220-1","DOI":"10.1038\/s41598-019-50220-1"},{"key":"10379_CR54","doi-asserted-by":"publisher","unstructured":"Nam, H.-J., & van Deursen, J. M. (2014). Cyclin B2 and p53 control proper timing of centrosome separation. Nature Cell Biology, 16, 535\u2013546. https:\/\/doi.org\/10.1038\/ncb2952","DOI":"10.1038\/ncb2952"},{"key":"10379_CR55","doi-asserted-by":"publisher","unstructured":"Pan, Q., et al. (2025). The SETDB1-PC4-UPF1 post-transcriptional machinery controls periodic degradation of CENPF mRNA and maintains mitotic progression. Cell Death & Differentiation, 32, 1413\u20131427. https:\/\/doi.org\/10.1038\/s41418-025-01465-z","DOI":"10.1038\/s41418-025-01465-z"},{"key":"10379_CR56","doi-asserted-by":"publisher","unstructured":"Guruvaiah, P., et al. (2023). ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE. Cell Death & Disease, 14, 456. https:\/\/doi.org\/10.1038\/s41419-023-05993-9","DOI":"10.1038\/s41419-023-05993-9"},{"key":"10379_CR57","doi-asserted-by":"publisher","unstructured":"Uxa, S., et al. (2021). Ki-67 gene expression. Cell Death & Differentiation, 28, 3357\u20133370. https:\/\/doi.org\/10.1038\/s41418-021-00823-x","DOI":"10.1038\/s41418-021-00823-x"},{"key":"10379_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi, S., et al. (2024). Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen\u2013targeted therapies. Proceedings of the National Academy of Sciences of the United States of America, 121. https:\/\/doi.org\/10.1073\/pnas.2322203121","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10379_CR59","doi-asserted-by":"publisher","unstructured":"Bluemn, E. G., et al. (2017). Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell, 32, 474\u2013489.e476. https:\/\/doi.org\/10.1016\/j.ccell.2017.09.003","DOI":"10.1016\/j.ccell.2017.09.003"},{"key":"10379_CR60","doi-asserted-by":"publisher","unstructured":"Pomerantz, M. M., et al. (2015). The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nature Genetics, 47, 1346\u20131351. https:\/\/doi.org\/10.1038\/ng.3419","DOI":"10.1038\/ng.3419"},{"key":"10379_CR61","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015). Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature Reviews Cancer, 15, 701\u2013711. https:\/\/doi.org\/10.1038\/nrc4016","journal-title":"Nature Reviews Cancer"},{"key":"10379_CR62","doi-asserted-by":"publisher","unstructured":"Li, C., Cheng, D. & Li, P. (2025). Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance. Frontiers in Oncology, 15, 2025. https:\/\/doi.org\/10.3389\/fonc.2025.1542811","DOI":"10.3389\/fonc.2025.1542811"},{"key":"10379_CR63","doi-asserted-by":"publisher","unstructured":"Chen, X., et al. (2024). Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate. Nature Communications, 15, 10675. https:\/\/doi.org\/10.1038\/s41467-024-53734-z","DOI":"10.1038\/s41467-024-53734-z"},{"key":"10379_CR64","doi-asserted-by":"publisher","unstructured":"Parolia, A., et al. (2024). NSD2 is a requisite subunit of the AR\/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. Nature Genetics, 56, 2132\u20132143. https:\/\/doi.org\/10.1038\/s41588-024-01893-6","DOI":"10.1038\/s41588-024-01893-6"},{"key":"10379_CR65","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies, A., et al. (2021). An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology, 23, 1023\u20131034. https:\/\/doi.org\/10.1038\/s41556-021-00743-5","journal-title":"Nature Cell Biology"},{"key":"10379_CR66","doi-asserted-by":"publisher","first-page":"10765","DOI":"10.1093\/nar\/gks888","volume":"40","author":"KF Decker","year":"2012","unstructured":"Decker, K. F., et al. (2012). Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Research, 40, 10765\u201310779. https:\/\/doi.org\/10.1093\/nar\/gks888","journal-title":"Nucleic Acids Research"},{"key":"10379_CR67","doi-asserted-by":"publisher","unstructured":"Jeon, H.-Y., et al. (2025). BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction. Nature Communications, 17, 670. https:\/\/doi.org\/10.1038\/s41467-025-67329-9","DOI":"10.1038\/s41467-025-67329-9"},{"key":"10379_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27077-y","volume":"12","author":"H Guo","year":"2021","unstructured":"Guo, H., et al. (2021). Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. Nature Communications, 12. https:\/\/doi.org\/10.1038\/s41467-021-27077-y","journal-title":"Nature Communications"},{"key":"10379_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2025.110000","volume":"189","author":"L Li","year":"2025","unstructured":"Li, L., Cho, K. H., Yu, X., & Cheng, S. (2025). Systematic multi-omics investigation of androgen receptor driven gene expression and epigenetics changes in prostate cancer. Computers in Biology and Medicine, 189. https:\/\/doi.org\/10.1016\/j.compbiomed.2025.110000","journal-title":"Computers in Biology and Medicine"},{"key":"10379_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02137-1","volume":"23","author":"L Chen","year":"2024","unstructured":"Chen, L., et al. (2024). Prostate cancer microenvironment: Multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota. Molecular Cancer, 23. https:\/\/doi.org\/10.1186\/s12943-024-02137-1","journal-title":"Molecular Cancer"},{"key":"10379_CR71","doi-asserted-by":"publisher","unstructured":"Hirz, T., et al. (2023) Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nature Communications, 14, 663. https:\/\/doi.org\/10.1038\/s41467-023-36325-2","DOI":"10.1038\/s41467-023-36325-2"},{"key":"10379_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00228-5","volume":"5","author":"J Liu","year":"2024","unstructured":"Liu, J., et al. (2024). Acetyltransferase NAT10 promotes an immunosuppressive microenvironment by modulating CD8+ T cell activity in prostate cancer. Molecular Biomedicine, 5,. https:\/\/doi.org\/10.1186\/s43556-024-00228-5","journal-title":"Molecular Biomedicine"},{"key":"10379_CR73","doi-asserted-by":"publisher","unstructured":"Zhu, Y., et al. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science Immunology, 8,. eade4656 https:\/\/doi.org\/10.1126\/sciimmunol.ade4656","DOI":"10.1126\/sciimmunol.ade4656"},{"key":"10379_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1552","volume":"14","author":"Q Ge","year":"2024","unstructured":"Ge, Q., et al. (2024). Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy prediction. Clinical and Translational Medicine, 14. https:\/\/doi.org\/10.1002\/ctm2.1552","journal-title":"Clinical and Translational Medicine"},{"key":"10379_CR75","doi-asserted-by":"publisher","unstructured":"Feng, D., et al. (2024). M2 macrophage-related molecular subtypes and prognostic index for prostate cancer patients through integrating single-cell and bulk RNA sequencing analysis. Genes & Diseases, 11, 101086. https:\/\/doi.org\/10.1016\/j.gendis.2023.101086","DOI":"10.1016\/j.gendis.2023.101086"},{"key":"10379_CR76","doi-asserted-by":"publisher","unstructured":"Su, W., et al. (2025). The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell, 43, 2171\u20132173. https:\/\/doi.org\/10.1016\/j.ccell.2025.10.005","DOI":"10.1016\/j.ccell.2025.10.005"},{"key":"10379_CR77","doi-asserted-by":"publisher","unstructured":"Yang, C., et al. (2022). Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. Immunity, 55, 1268\u20131283.e1269. https:\/\/doi.org\/10.1016\/j.immuni.2022.05.012","DOI":"10.1016\/j.immuni.2022.05.012"},{"key":"10379_CR78","doi-asserted-by":"publisher","unstructured":"Kwon, H., et al. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Science Immunology, 7, eabq2630. https:\/\/doi.org\/10.1126\/sciimmunol.abq2630","DOI":"10.1126\/sciimmunol.abq2630"},{"key":"10379_CR79","doi-asserted-by":"publisher","unstructured":"Guan, X., et al. (2022). Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature, 606, 791\u2013796. https:\/\/doi.org\/10.1038\/s41586-022-04522-6","DOI":"10.1038\/s41586-022-04522-6"},{"key":"10379_CR80","doi-asserted-by":"publisher","first-page":"9335","DOI":"10.18632\/oncotarget.2429","volume":"5","author":"A Ardiani","year":"2014","unstructured":"Ardiani, A., Gameiro, S. R., Kwilas, A. R., Donahue, R. N., & Hodge, J. W. (2014). Androgen deprivation therapy sensitizes prostate cancer cells to Tcell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget, 5, 9335\u20139348. https:\/\/doi.org\/10.18632\/oncotarget.2429","journal-title":"Oncotarget"},{"key":"10379_CR81","doi-asserted-by":"publisher","unstructured":"Dallos, M. C., et al. (2024). Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer. Clinical Cancer Research, 30, 5218\u20135230. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0060","DOI":"10.1158\/1078-0432.CCR-24-0060"},{"key":"10379_CR82","doi-asserted-by":"publisher","unstructured":"Gannon, P. O., et al. (2009). Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. Journal of Immunological Methods, 348, 9\u201317. https:\/\/doi.org\/10.1016\/j.jim.2009.06.004","DOI":"10.1016\/j.jim.2009.06.004"},{"key":"10379_CR83","doi-asserted-by":"publisher","unstructured":"Cioni, B., et al. (2020). Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion. Nature Communications, 11, 4498. https:\/\/doi.org\/10.1038\/s41467-020-18313-y","DOI":"10.1038\/s41467-020-18313-y"},{"key":"10379_CR84","doi-asserted-by":"publisher","unstructured":"Wang, D., et al. (2023). IL-1\u03b2 is an androgen-responsive target in macrophages for immunotherapy of prostate cancer. Advanced Science, 10, 2206889. https:\/\/doi.org\/10.1002\/advs.202206889","DOI":"10.1002\/advs.202206889"},{"key":"10379_CR85","doi-asserted-by":"publisher","unstructured":"Karki, R., & Kanneganti, T.-D. (2019). Diverging inflammasome signals in tumorigenesis and potential targeting. Nature Reviews Cancer, 19, 197\u2013214. https:\/\/doi.org\/10.1038\/s41568-019-0123-y","DOI":"10.1038\/s41568-019-0123-y"},{"key":"10379_CR86","doi-asserted-by":"publisher","unstructured":"Song, X., et al. (2005). CD11b+\/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1\u03b2-secreting cells1. The Journal of Immunology, 175, 8200\u20138208. https:\/\/doi.org\/10.4049\/jimmunol.175.12.8200","DOI":"10.4049\/jimmunol.175.12.8200"},{"key":"10379_CR87","doi-asserted-by":"publisher","unstructured":"Tu, S., et al. (2008). Overexpression of Interleukin-1\u03b2 Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice. Cancer Cell, 14, 408\u2013419. https:\/\/doi.org\/10.1016\/j.ccr.2008.10.011","DOI":"10.1016\/j.ccr.2008.10.011"},{"key":"10379_CR88","doi-asserted-by":"publisher","unstructured":"Antonarakis, E. S., et al. (2019). Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study. Journal of Clinical Oncology, 38, 395\u2013405. https:\/\/doi.org\/10.1200\/JCO.19.01638","DOI":"10.1200\/JCO.19.01638"},{"key":"10379_CR89","doi-asserted-by":"publisher","unstructured":"Beer, T. M., et al. (2016). Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. Journal of Clinical Oncology, 35, 40\u201347. https:\/\/doi.org\/10.1200\/JCO.2016.69.1584","DOI":"10.1200\/JCO.2016.69.1584"},{"key":"10379_CR90","doi-asserted-by":"publisher","unstructured":"Yu, H., et al. (2026). Integrated single-cell and spatial transcriptomic profiling decodes lineage plasticity and immune microenvironment remodeling in prostate cancer progression. Molecular Cancer, 86, 1113\u20131131. https:\/\/doi.org\/10.1186\/s12943-026-02617-6","DOI":"10.1186\/s12943-026-02617-6"},{"key":"10379_CR91","doi-asserted-by":"publisher","unstructured":"Ge, Q., et al. (2026). Integrative single-cell and spatial transcriptomics with explainable AI reveal lethal prognostic axis in prostate cancer. npj Digital Medicine, 9, 119. https:\/\/doi.org\/10.1038\/s41746-025-02297-4","DOI":"10.1038\/s41746-025-02297-4"},{"key":"10379_CR92","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","volume":"26","author":"AZ Obradovic","year":"2020","unstructured":"Obradovic, A. Z., et al. (2020). T-cell infiltration and adaptive Treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer. Clinical Cancer Research, 26, 3182\u20133192. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3372","journal-title":"Clinical Cancer Research"},{"key":"10379_CR93","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41391-017-0013-x","volume":"21","author":"Y-C Shen","year":"2018","unstructured":"Shen, Y.-C., et al. (2018). Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): Preclinical activity in the Myc-CaP model. Prostate Cancer and Prostatic Diseases, 21, 113\u2013125. https:\/\/doi.org\/10.1038\/s41391-017-0013-x","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"10379_CR94","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41422-018-0089-4","volume":"28","author":"C Wang","year":"2018","unstructured":"Wang, C., et al. (2018). Elimination of CD4lowHLA-G+ T cells overcomes castration-resistance in prostate cancer therapy. Cell Research, 28, 1103\u20131117. https:\/\/doi.org\/10.1038\/s41422-018-0089-4","journal-title":"Cell Research"},{"key":"10379_CR95","doi-asserted-by":"publisher","unstructured":"Feng, S., et al. (2018). Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. Proceedings of the National Academy of Sciences, 115, 10094\u201310099. https:\/\/doi.org\/10.1073\/pnas.1800695115","DOI":"10.1073\/pnas.1800695115"},{"key":"10379_CR96","doi-asserted-by":"publisher","unstructured":"Wang, Q., et al. (2025). AR+TREM2+ macrophage induced pathogenic immunosuppression promotes prostate cancer progression. Nature Communications, 16, 6964. https:\/\/doi.org\/10.1038\/s41467-025-62381-x","DOI":"10.1038\/s41467-025-62381-x"},{"key":"10379_CR97","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu, A., et al. (2025). Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature, 637, 1207\u20131217. https:\/\/doi.org\/10.1038\/s41586-024-08290-3","journal-title":"Nature"},{"key":"10379_CR98","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","volume":"623","author":"C Guo","year":"2023","unstructured":"Guo, C., et al. (2023). Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature, 623, 1053\u20131061. https:\/\/doi.org\/10.1038\/s41586-023-06696-z","journal-title":"Nature"},{"key":"10379_CR99","doi-asserted-by":"publisher","unstructured":"Li, N., et al. (2022). ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nature Communications, 13, 7281. https:\/\/doi.org\/10.1038\/s41467-022-34871-9","DOI":"10.1038\/s41467-022-34871-9"},{"key":"10379_CR100","doi-asserted-by":"publisher","unstructured":"Zhang, J., et al. (2025). Prostate cancer cells secrete PD-1 in exosomes to enhance myeloid-derived suppressor cell activity and promote tumor immune evasion. Cancer Research, 85, 3435\u20133453. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-3748","DOI":"10.1158\/0008-5472.CAN-24-3748"},{"key":"10379_CR101","doi-asserted-by":"publisher","unstructured":"Kittane, S., et al. (2025). The histone methyltransferase KMT2D is a critical mediator of lineage plasticity and therapeutic response in castration resistant prostate cancer. Cancer Research. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-2053","DOI":"10.1158\/0008-5472.CAN-25-2053"},{"key":"10379_CR102","doi-asserted-by":"publisher","unstructured":"Chen, L., et al. (2025). PFKFB3 as a multifaceted driver and therapeutic target in castration-resistant prostate cancer. Cell Death & Disease, 16, 760. https:\/\/doi.org\/10.1038\/s41419-025-08089-8","DOI":"10.1038\/s41419-025-08089-8"},{"key":"10379_CR103","doi-asserted-by":"publisher","unstructured":"George, D. J., et al. (2020). Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 38, 79.e15\u201379.e22. https:\/\/doi.org\/10.1016\/j.urolonc.2019.08.015","DOI":"10.1016\/j.urolonc.2019.08.015"},{"key":"10379_CR104","doi-asserted-by":"publisher","unstructured":"Kaushik, A. K., et al. (2016). Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nature Communications, 7, 11612. https:\/\/doi.org\/10.1038\/ncomms11612","DOI":"10.1038\/ncomms11612"},{"key":"10379_CR105","doi-asserted-by":"publisher","unstructured":"Pfeil, K., et al. (2004). Long-term androgen-ablation causes increased resistance to PI3K\/Akt pathway inhibition in prostate cancer cells. The Prostate, 58, 259\u2013268. https:\/\/doi.org\/10.1002\/pros.10332","DOI":"10.1002\/pros.10332"},{"key":"10379_CR106","doi-asserted-by":"publisher","unstructured":"Li, J., et al. (2024). Androgen-targeted hsa_circ_0085121 encodes a novel protein and improves the development of prostate cancer through facilitating the activity of PI3K\/Akt\/mTOR pathway and enhancing AR-V7 alternative splicing. Cell Death & Disease, 15, 848. https:\/\/doi.org\/10.1038\/s41419-024-07246-9","DOI":"10.1038\/s41419-024-07246-9"},{"key":"10379_CR107","doi-asserted-by":"publisher","unstructured":"Yin, L., et al. (2025). PSMA-targeted nanoparticles with PI3K\/mTOR dual inhibitor downregulate P-glycoprotein and inactivate myeloid-derived suppressor cells for enhanced chemotherapy and immunotherapy in prostate cancer. Advanced Materials, 37, 2415322. https:\/\/doi.org\/10.1002\/adma.202415322","DOI":"10.1002\/adma.202415322"},{"key":"10379_CR108","doi-asserted-by":"publisher","unstructured":"Sun, Y., et al. (2025). Targeting CXCR2 in prostate cancer cells can block CD47-SIRP\u03b1 interaction and reverse M2 macrophage polarization in the TME. Molecular Cancer, 24, 273. https:\/\/doi.org\/10.1186\/s12943-025-02436-1","DOI":"10.1186\/s12943-025-02436-1"},{"key":"10379_CR109","doi-asserted-by":"publisher","unstructured":"Wang, X., et al. (2022). FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Oncogene, 41, 4259\u20134270. https:\/\/doi.org\/10.1038\/s41388-022-02423-6","DOI":"10.1038\/s41388-022-02423-6"},{"key":"10379_CR110","doi-asserted-by":"publisher","unstructured":"Liu, Y., Zhou, Q., Ye, F., Yang, C., & Jiang, H. (2023). Gut microbiota-derived short-chain fatty acids promote prostate cancer progression via inducing cancer cell autophagy and M2 macrophage polarization. Neoplasia, 43, 100928. https:\/\/doi.org\/10.1016\/j.neo.2023.100928","DOI":"10.1016\/j.neo.2023.100928"},{"key":"10379_CR111","doi-asserted-by":"publisher","unstructured":"El-Kenawi, A., et al. (2021) Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Research, 81, 5477\u20135490. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-4028","DOI":"10.1158\/0008-5472.CAN-20-4028"},{"key":"10379_CR112","doi-asserted-by":"publisher","unstructured":"Li, X.-F. et al., (2023). Macrophages promote anti-androgen resistance in prostate cancer bone disease. Journal of Experimental Medicine, 220, e20221007. https:\/\/doi.org\/10.1084\/jem.20221007","DOI":"10.1084\/jem.20221007"},{"key":"10379_CR113","doi-asserted-by":"publisher","unstructured":"Luo, Y., et al. (2026). ANXA2-mediated phagocytosis generates AR+ macrophages to confer enzalutamide resistance in prostate cancer. Advanced Science, n\/a, e75290. https:\/\/doi.org\/10.1002\/advs.75290","DOI":"10.1002\/advs.75290"},{"key":"10379_CR114","doi-asserted-by":"publisher","unstructured":"Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017). Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology, 14, 399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217","DOI":"10.1038\/nrclinonc.2016.217"},{"key":"10379_CR115","doi-asserted-by":"publisher","unstructured":"Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022). Macrophages as tools and targets in cancer therapy. Nature Reviews Drug Discovery, 21, 799\u2013820. https:\/\/doi.org\/10.1038\/s41573-022-00520-5","DOI":"10.1038\/s41573-022-00520-5"},{"key":"10379_CR116","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","volume":"10","author":"Q Yang","year":"2020","unstructured":"Yang, Q., et al. (2020). The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharmaceutica Sinica B, 10, 2156\u20132170. https:\/\/doi.org\/10.1016\/j.apsb.2020.04.004","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10379_CR117","doi-asserted-by":"publisher","unstructured":"Niu, N., et al. (2024). Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Cancer Cell, 42, 869\u2013884.e869.  https:\/\/doi.org\/10.1016\/j.ccell.2024.03.005","DOI":"10.1016\/j.ccell.2024.03.005"},{"key":"10379_CR118","doi-asserted-by":"publisher","unstructured":"Han, X., et al. (2024). Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment. Cell Reports, 43, 114972.  https:\/\/doi.org\/10.1016\/j.celrep.2024.114972","DOI":"10.1016\/j.celrep.2024.114972"},{"key":"10379_CR119","doi-asserted-by":"publisher","unstructured":"Forsthuber, A., et al. (2024). Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy. Nature Communications, 15, 9678. https:\/\/doi.org\/10.1038\/s41467-024-53908-9","DOI":"10.1038\/s41467-024-53908-9"},{"key":"10379_CR120","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1038\/s41388-025-03569-9","volume":"44","author":"Y Ren","year":"2025","unstructured":"Ren, Y., et al. (2025). Cancer-associated fibroblasts drive lung adenocarcinoma progression via THBS2-mediated epithelial-mesenchymal transition. Oncogene, 44, 4284\u20134297. https:\/\/doi.org\/10.1038\/s41388-025-03569-9","journal-title":"Oncogene"},{"key":"10379_CR121","doi-asserted-by":"publisher","unstructured":"Zhang, B., et al.  (2024). Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts. The Journal of Clinical Investigation, 134. https:\/\/doi.org\/10.1172\/JCI175949","DOI":"10.1172\/JCI175949"},{"key":"10379_CR122","doi-asserted-by":"publisher","unstructured":"Heide, J., et al. (2025). NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature, 645, 1051\u20131059. https:\/\/doi.org\/10.1038\/s41586-025-09303-5","DOI":"10.1038\/s41586-025-09303-5"},{"key":"10379_CR123","doi-asserted-by":"publisher","unstructured":"Zhuang, J., et al. (2023). Cancer-associated fibroblast\u2013derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance. Cancer Research, 83, 1611\u20131627. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2213","DOI":"10.1158\/0008-5472.CAN-22-2213"},{"issue":"1","key":"10379_CR124","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41421-023-00529-z","volume":"9","author":"G-Q Zhu","year":"2023","unstructured":"Zhu, G.-Q., et al. (2023). CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discovery, 9(1), 25. https:\/\/doi.org\/10.1038\/s41421-023-00529-z","journal-title":"Cell Discovery"},{"key":"10379_CR125","doi-asserted-by":"publisher","unstructured":"Ling, S., et al. (2025). Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria. Nature Communications, 16, 4392. https:\/\/doi.org\/10.1038\/s41467-025-59745-8","DOI":"10.1038\/s41467-025-59745-8"},{"key":"10379_CR126","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1172\/JCI99159","volume":"128","author":"A Clocchiatti","year":"2018","unstructured":"Clocchiatti, A., et al. (2018). Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. Journal of Clinical Investigation, 128, 5531\u20135548. https:\/\/doi.org\/10.1172\/JCI99159","journal-title":"Journal of Clinical Investigation"},{"key":"10379_CR127","doi-asserted-by":"publisher","unstructured":"Ghosh, S., et al. (2024). Nuclear lamin A\/C phosphorylation by loss of androgen receptor leads to cancer-associated fibroblast activation. Nature Communications, 15, 7984. https:\/\/doi.org\/10.1038\/s41467-024-52344-z","DOI":"10.1038\/s41467-024-52344-z"},{"key":"10379_CR128","doi-asserted-by":"publisher","unstructured":"Mazzeo, L., et al. (2024). ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation. Nature Communications, 15, 1038. https:\/\/doi.org\/10.1038\/s41467-024-45308-w","DOI":"10.1038\/s41467-024-45308-w"},{"key":"10379_CR129","doi-asserted-by":"publisher","unstructured":"Zhang, Z., et al. (2020). Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell, 38, 279\u2013296.e279. https:\/\/doi.org\/10.1016\/j.ccell.2020.06.005","DOI":"10.1016\/j.ccell.2020.06.005"},{"key":"10379_CR130","doi-asserted-by":"publisher","unstructured":"Wang, H., et al. (2023). Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell, 41, 1345\u20131362.e1349. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.016","DOI":"10.1016\/j.ccell.2023.05.016"},{"key":"10379_CR131","doi-asserted-by":"publisher","unstructured":"Zhang, K., et al. (2024). Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer. Nature Communications, 15, 9050. https:\/\/doi.org\/10.1038\/s41467-024-53233-1","DOI":"10.1038\/s41467-024-53233-1"},{"key":"10379_CR132","doi-asserted-by":"publisher","unstructured":"Caligiuri, G. & Tuveson, D. A. (2023). Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell, 41, 434\u2013449. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.015","DOI":"10.1016\/j.ccell.2023.02.015"},{"key":"10379_CR133","doi-asserted-by":"publisher","unstructured":"Kalluri, R. (2016). The biology and function of fibroblasts in cancer. Nature Reviews Cancer, 16, 582\u2013598. https:\/\/doi.org\/10.1038\/nrc.2016.73","DOI":"10.1038\/nrc.2016.73"},{"key":"10379_CR134","doi-asserted-by":"publisher","unstructured":"Ye, J., et al. (2024). Senescent CAFs mediate immunosuppression and drive breast cancer progression. Cancer Discovery, 14, 1302\u20131323. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0426","DOI":"10.1158\/2159-8290.CD-23-0426"},{"key":"10379_CR135","doi-asserted-by":"publisher","unstructured":"Fang, H., et al. (2024). myCAF-derived exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment. Journal of Hematology & Oncology, 17, 126. https:\/\/doi.org\/10.1186\/s13045-024-01643-5","DOI":"10.1186\/s13045-024-01643-5"},{"key":"10379_CR136","doi-asserted-by":"publisher","unstructured":"Pei, G., et al. (2025). Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Nature, 642, 212\u2013221. https:\/\/doi.org\/10.1038\/s41586-025-08927-x","DOI":"10.1038\/s41586-025-08927-x"},{"key":"10379_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07270-9","volume":"16","author":"H Bai","year":"2025","unstructured":"Bai, H., et al. (2025). ERG mediates the differentiation of hepatic progenitor cells towards immunosuppressive PDGFR\u03b1+ cancer-associated fibroblasts during hepatocarcinogenesis. Cell Death & Disease, 16. https:\/\/doi.org\/10.1038\/s41419-024-07270-9","journal-title":"Cell Death & Disease"},{"key":"10379_CR138","doi-asserted-by":"publisher","unstructured":"Brunner, E., et al. (2025). Unraveling the YAP1-TGF\u03b21 axis: A key driver of androgen receptor loss in prostate cancer-associated fibroblasts. Journal of Experimental & Clinical Cancer Research, 45, 11. https:\/\/doi.org\/10.1186\/s13046-025-03578-2","DOI":"10.1186\/s13046-025-03578-2"},{"key":"10379_CR139","doi-asserted-by":"publisher","unstructured":"Zhao, D., et al. (2026). Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer. Science Advances, 12, eady5324. https:\/\/doi.org\/10.1126\/sciadv.ady5324","DOI":"10.1126\/sciadv.ady5324"},{"key":"10379_CR140","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.62347\/OTTR3398","volume":"14","author":"C Wang","year":"2024","unstructured":"Wang, C. (2024). NRG1 secreted by cancer-associated fibroblasts contributes to enzalutamide resistance in prostate cancer cells. American Journal of Cancer Research, 14, 4830\u20134840. https:\/\/doi.org\/10.62347\/OTTR3398","journal-title":"American Journal of Cancer Research"},{"key":"10379_CR141","doi-asserted-by":"publisher","unstructured":"Ishii, K., et al. (2019). Loss of fibroblast-dependent androgen receptor activation in prostate cancer cells is involved in the mechanism of acquired resistance to castration. Journal of Clinical Medicine, 8, 1379. https:\/\/doi.org\/10.3390\/jcm8091379","DOI":"10.3390\/jcm8091379"},{"key":"10379_CR142","doi-asserted-by":"publisher","unstructured":"Nickols, N. G., et al. (2019). MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 22, 531\u2013538. https:\/\/doi.org\/10.1038\/s41391-019-0134-5","DOI":"10.1038\/s41391-019-0134-5"},{"key":"10379_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05773-5","volume":"14","author":"Y Li","year":"2023","unstructured":"Li, Y., et al. (2023). Post-transcriptional modification of m6A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer. Cell Death & Disease, 14. https:\/\/doi.org\/10.1038\/s41419-023-05773-5","journal-title":"Cell Death & Disease"},{"key":"10379_CR144","doi-asserted-by":"publisher","unstructured":"Li, X., et al. (2025). Diet-metabolism-transcription axis modulates the sensitivity to CDK4\/6 inhibitors through RB1 in prostate cancer. Cell Reports, 44. https:\/\/doi.org\/10.1016\/j.celrep.2025.116530","DOI":"10.1016\/j.celrep.2025.116530"},{"key":"10379_CR145","doi-asserted-by":"publisher","unstructured":"Glunde, K., Bhujwalla, Z. M., & Ronen, S. M. (2011). Choline metabolism in malignant transformation. Nature Reviews Cancer, 11, 835\u201384. https:\/\/doi.org\/10.1038\/nrc3162","DOI":"10.1038\/nrc3162"},{"key":"10379_CR146","doi-asserted-by":"publisher","unstructured":"Tortorella, E., Giantulli, S., Sciarra, A., & Silvestri, I. (2023). AR and PI3K\/AKT in prostate cancer: A tale of two interconnected pathways. International Journal of Molecular Sciences, 24,\u00a02046. https:\/\/doi.org\/10.3390\/ijms24032046","DOI":"10.3390\/ijms24032046"},{"key":"10379_CR147","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","volume":"35","author":"L Cato","year":"2019","unstructured":"Cato, L., et al. (2019). ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer. Cancer Cell, 35, 401-413.e406. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.008","journal-title":"Cancer Cell"},{"key":"10379_CR148","doi-asserted-by":"publisher","unstructured":"Cui, D., et al. (2023). Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. The Journal of Clinical Investigation, 133, e161913. https:\/\/doi.org\/10.1172\/JCI161913","DOI":"10.1172\/JCI161913"},{"key":"10379_CR149","doi-asserted-by":"publisher","unstructured":"Hearn, J. W. D., et al. (2020). HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer. JAMA Oncology, 6, e196496-e196496. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6496","DOI":"10.1001\/jamaoncol.2019.6496"},{"key":"10379_CR150","doi-asserted-by":"publisher","unstructured":"Qin, L., et al. (2024). Chronic hypoxia stabilizes 3\u03b2HSD1 via autophagy suppression. Cell Reports, 43, 11357. https:\/\/doi.org\/10.1016\/j.celrep.2023.113575","DOI":"10.1016\/j.celrep.2023.113575"},{"key":"10379_CR151","doi-asserted-by":"publisher","unstructured":"Fromont, G., et al. (2012). Biological significance of perineural invasion (PNI) in prostate cancer. The Prostate, 72, 542\u2013548. https:\/\/doi.org\/10.1002\/pros.21456","DOI":"10.1002\/pros.21456"},{"key":"10379_CR152","doi-asserted-by":"publisher","unstructured":"Hoover, G., et al. (2025). Nerve-to-cancer transfer of mitochondria during cancer metastasis. Nature, 644, 252\u2013262. https:\/\/doi.org\/10.1038\/s41586-025-09176-8","DOI":"10.1038\/s41586-025-09176-8"},{"key":"10379_CR153","doi-asserted-by":"publisher","unstructured":"Shi, X., et al. (2026). Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia. Cancer Cell, 44, 949\u2013964.e946. https:\/\/doi.org\/10.1016\/j.ccell.2026.01.014","DOI":"10.1016\/j.ccell.2026.01.014"},{"key":"10379_CR154","doi-asserted-by":"publisher","unstructured":"Padmanaban, V., et al. (2024). Neuronal substance P drives metastasis through an extracellular RNA\u2013TLR7 axis. Nature, 633, 207\u2013215. https:\/\/doi.org\/10.1038\/s41586-024-07767-5","DOI":"10.1038\/s41586-024-07767-5"},{"key":"10379_CR155","doi-asserted-by":"publisher","unstructured":"Thulin, M. H., et al. (2025). Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis. Journal of Translational Medicine, 23, 672. https:\/\/doi.org\/10.1186\/s12967-025-06644-7","DOI":"10.1186\/s12967-025-06644-7"},{"key":"10379_CR156","doi-asserted-by":"publisher","unstructured":"Goto, Y., et al. (2020). Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK\u2013YAP signaling axis. Oncogene, 39, 4014\u20134027. https:\/\/doi.org\/10.1038\/s41388-020-1272-x","DOI":"10.1038\/s41388-020-1272-x"},{"key":"10379_CR157","doi-asserted-by":"publisher","unstructured":"Wang, N., et al. (2015). Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM\/CaMKK\u2013mediated phosphorylation of Akt. Clinical Cancer Research, 21, 4676\u20134685. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3163","DOI":"10.1158\/1078-0432.CCR-14-3163"},{"key":"10379_CR158","doi-asserted-by":"publisher","unstructured":"Sigorski, D., Gulczy\u0144ski, J., Sejda, A., Rogowski, W., & I\u017cycka-\u015awieszewska, E. (2021). Investigation of neural microenvironment in prostate cancer in context of neural density, perineural invasion, and neuroendocrine profile of tumors. Frontiers in Oncology, 11. https:\/\/doi.org\/10.3389\/fonc.2021.710899","DOI":"10.3389\/fonc.2021.710899"},{"key":"10379_CR159","doi-asserted-by":"publisher","unstructured":"Delahunt, B., et al. (2020). Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. Histopathology, 77, 284\u2013292. https:\/\/doi.org\/10.1111\/his.14107","DOI":"10.1111\/his.14107"},{"key":"10379_CR160","doi-asserted-by":"publisher","unstructured":"Anderson, P. R., Hanlon, A. L., Patchefsky, A., Al-Saleem, T., & Hanks, G. E. (1998). Perineural invasion and Gleason 7\u201310 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng\/ml treated with conformal external beam radiation therapy. International Journal of Radiation\u00b7Oncology\u00b7Biology Physics, 41, 1087\u20131092. https:\/\/doi.org\/10.1016\/S0360-3016(98)00167-9","DOI":"10.1016\/S0360-3016(98)00167-9"},{"key":"10379_CR161","doi-asserted-by":"publisher","unstructured":"Maru, N., Ohori, M., Kattan, M. W., Scardino, P. T., & Wheeler, T. M. (2001). Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Human Pathology, 32, 828\u2013833. https:\/\/doi.org\/10.1053\/hupa.2001.26456","DOI":"10.1053\/hupa.2001.26456"},{"key":"10379_CR162","doi-asserted-by":"publisher","unstructured":"Dwivedi, S., et al. (2021). Sympathetic signaling facilitates progression of neuroendocrine prostate cancer. Cell Death Discovery, 7, 364. https:\/\/doi.org\/10.1038\/s41420-021-00752-1","DOI":"10.1038\/s41420-021-00752-1"},{"key":"10379_CR163","doi-asserted-by":"publisher","unstructured":"Banh, R. S., et al. (2020). Neurons release serine to support mRNA translation in pancreatic cancer. Cell, 183, 1202\u20131218.e1225. https:\/\/doi.org\/10.1016\/j.cell.2020.10.016","DOI":"10.1016\/j.cell.2020.10.016"},{"key":"10379_CR164","doi-asserted-by":"publisher","unstructured":"Ren, L., et al. (2025). Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Cancer Cell, 43, 2241\u20132258.e2248. https:\/\/doi.org\/10.1016\/j.ccell.2025.09.003","DOI":"10.1016\/j.ccell.2025.09.003"},{"key":"10379_CR165","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1016\/j.cell.2025.09.029","volume":"188","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y., et al. (2025). Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. Cell, 188, 6754-6773.e6729. https:\/\/doi.org\/10.1016\/j.cell.2025.09.029","journal-title":"Cell"},{"key":"10379_CR166","doi-asserted-by":"publisher","unstructured":"Liu, Y.-N., et al. (2024). Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer. Molecular Oncology, 18, 1665\u20131686. https:\/\/doi.org\/10.1002\/1878-0261.13614","DOI":"10.1002\/1878-0261.13614"},{"key":"10379_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01549-1","volume":"4","author":"W-Y Chen","year":"2021","unstructured":"Chen, W.-Y., et al. (2021). Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. Communications Biology, 4. https:\/\/doi.org\/10.1038\/s42003-020-01549-1","journal-title":"Communications Biology"},{"key":"10379_CR168","doi-asserted-by":"publisher","unstructured":"Di Donato, M., Cernera, G., Auricchio, F., Migliaccio, A., & Castoria, G. (2018). Cross-talk between androgen receptor and nerve growth factor receptor in prostate cancer cells: implications for a new therapeutic approach. Cell Death Discovery, 4, 5. https:\/\/doi.org\/10.1038\/s41420-017-0024-3","DOI":"10.1038\/s41420-017-0024-3"},{"key":"10379_CR169","doi-asserted-by":"publisher","unstructured":"Singh, R., et al. (2018). TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. The Journal of Clinical Investigation, 128, 3129\u20133143. https:\/\/doi.org\/10.1172\/JCI96060","DOI":"10.1172\/JCI96060"},{"key":"10379_CR170","doi-asserted-by":"publisher","unstructured":"Zhang, Y., et al. (2023). FBXO22 mediates the NGF\/TRKA signaling pathway in bone metastases in prostate cancer. The American Journal of Pathology, 193, 1248\u20131266. https:\/\/doi.org\/10.1016\/j.ajpath.2023.05.012","DOI":"10.1016\/j.ajpath.2023.05.012"},{"key":"10379_CR171","doi-asserted-by":"publisher","unstructured":"Chen, W.-Y., et al. (2019). Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer. Cancer Letters, 440\u2013441, 35\u201346. https:\/\/doi.org\/10.1016\/j.canlet.2018.10.004","DOI":"10.1016\/j.canlet.2018.10.004"},{"key":"10379_CR172","doi-asserted-by":"publisher","unstructured":"Ku, S. Y., et al. (2017). Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science, 355, 78\u201383. https:\/\/doi.org\/10.1126\/science.aah4199","DOI":"10.1126\/science.aah4199"},{"key":"10379_CR173","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H., et al. (2016). Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 22, 298\u2013305. https:\/\/doi.org\/10.1038\/nm.4045","journal-title":"Nature Medicine"},{"key":"10379_CR174","doi-asserted-by":"publisher","unstructured":"Yamada, Y., & Beltran, H. (2021). Clinical and biological features of neuroendocrine prostate cancer. Current Oncology Reports, 23, 15. https:\/\/doi.org\/10.1007\/s11912-020-01003-9","DOI":"10.1007\/s11912-020-01003-9"},{"key":"10379_CR175","doi-asserted-by":"publisher","unstructured":"Romero, R., et al. (2024). The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nature Cancer, 5, 1641\u20131659. https:\/\/doi.org\/10.1038\/s43018-024-00838-6","DOI":"10.1038\/s43018-024-00838-6"},{"key":"10379_CR176","doi-asserted-by":"publisher","unstructured":"Dardenne, E., et al. (2016). N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell, 30, 563\u2013577. https:\/\/doi.org\/10.1016\/j.ccell.2016.09.005","DOI":"10.1016\/j.ccell.2016.09.005"},{"key":"10379_CR177","doi-asserted-by":"publisher","unstructured":"Xu, P., et al. (2024). Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature Communications, 15, 6626. https:\/\/doi.org\/10.1038\/s41467-024-50459-x","DOI":"10.1038\/s41467-024-50459-x"},{"key":"10379_CR178","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/0008-5472.CAN-20-3351","volume":"81","author":"K Unno","year":"2021","unstructured":"Unno, K., et al. (2021). Activated ALK cooperates with N-Myc via Wnt\/\u03b2-catenin signaling to induce neuroendocrine prostate cancer. Cancer Research, 81, 2157\u20132170. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3351","journal-title":"Cancer Research"},{"key":"10379_CR179","doi-asserted-by":"publisher","unstructured":"Davies, A. H., Beltran, H., & Zoubeidi, A. (2018). Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nature Reviews Urology, 15, 271\u2013286. https:\/\/doi.org\/10.1038\/nrurol.2018.22","DOI":"10.1038\/nrurol.2018.22"},{"key":"10379_CR180","doi-asserted-by":"publisher","unstructured":"Cejas, P., et al. (2021). Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications, 12, 5775. https:\/\/doi.org\/10.1038\/s41467-021-26042-z","DOI":"10.1038\/s41467-021-26042-z"},{"key":"10379_CR181","doi-asserted-by":"publisher","unstructured":"Lu, X., et al. (2025). NKX2\u20131 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling. Nature Genetics, 57, 1966\u20131980. https:\/\/doi.org\/10.1038\/s41588-025-02265-4","DOI":"10.1038\/s41588-025-02265-4"},{"key":"10379_CR182","doi-asserted-by":"publisher","unstructured":"Singh, R., et al. (2026). Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity. Nature Communications, 17, 2992. https:\/\/doi.org\/10.1038\/s41467-026-69308-0","DOI":"10.1038\/s41467-026-69308-0"},{"key":"10379_CR183","doi-asserted-by":"publisher","unstructured":"Tang, D. G. (2025). Serotonin sets up neutrophil extracellular traps to promote neuroendocrine prostate cancer metastasis in the liver. The Journal of Clinical Investigation, 135. https:\/\/doi.org\/10.1172\/JCI191687","DOI":"10.1172\/JCI191687"},{"key":"10379_CR184","doi-asserted-by":"publisher","unstructured":"Chambers, C. R., et al. (n.d.). Targeting the NPY\/NPY1R signaling axis in mutant p53\u2013dependent pancreatic cancer impairs metastasis. Science Advances, 11, eadq4416. https:\/\/doi.org\/10.1126\/sciadv.adq4416","DOI":"10.1126\/sciadv.adq4416"},{"key":"10379_CR185","doi-asserted-by":"publisher","unstructured":"Terrisse, S., et al. (2020). Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: A meta-analysis of individual patient data from randomized clinical trials. JAMA Oncology, 6, 206\u2013216. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4097","DOI":"10.1001\/jamaoncol.2019.4097"},{"key":"10379_CR186","doi-asserted-by":"publisher","unstructured":"Zhu, J., Shen, C., Wang, Z., Chen, F., & Wang, T. (2026). Predictive risk model for bone metastasis in intermediate-risk prostate cancer: A single-center retrospective analysis. Scientific Reports, 16, 23032. https:\/\/doi.org\/10.1038\/s41598-026-53745-4","DOI":"10.1038\/s41598-026-53745-4"},{"key":"10379_CR187","doi-asserted-by":"publisher","unstructured":"Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025). Prostate cancer: A review. JAMA, 333, 1433\u20131446. https:\/\/doi.org\/10.1001\/jama.2025.0228","DOI":"10.1001\/jama.2025.0228"},{"key":"10379_CR188","doi-asserted-by":"publisher","unstructured":"Logothetis, C. J. & Lin, S.-H. (2005). Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer, 5, 21\u201328. https:\/\/doi.org\/10.1038\/nrc1528","DOI":"10.1038\/nrc1528"},{"key":"10379_CR189","doi-asserted-by":"publisher","unstructured":"Satcher, R. L. & Zhang, X. H. F. (2022). Evolving cancer\u2013niche interactions and therapeutic targets during bone metastasis. Nature Reviews Cancer, 22, 85\u2013101. https:\/\/doi.org\/10.1038\/s41568-021-00406-5","DOI":"10.1038\/s41568-021-00406-5"},{"key":"10379_CR190","doi-asserted-by":"publisher","unstructured":"Croucher, P. I., McDonald, M. M., & Martin, T. J. (2016). Bone metastasis: The importance of the neighbourhood. Nature Reviews Cancer, 16, 373\u2013386. https:\/\/doi.org\/10.1038\/nrc.2016.44","DOI":"10.1038\/nrc.2016.44"},{"key":"10379_CR191","doi-asserted-by":"publisher","unstructured":"Yu, G., et al. (2022). Retinoic acid receptor activation reduces metastatic prostate cancer bone lesions by blocking the endothelial-to-osteoblast transition. Cancer Research, 82, 3158\u20133171. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0170","DOI":"10.1158\/0008-5472.CAN-22-0170"},{"key":"10379_CR192","doi-asserted-by":"publisher","unstructured":"Zhang, J., et al. (2001). Osteoprotegerin inhibits prostate cancer\u2013induced osteoclastogenesis and prevents prostate tumor growth in the bone. The Journal of Clinical Investigation, 107, 1235\u20131244. https:\/\/doi.org\/10.1172\/JCI11685","DOI":"10.1172\/JCI11685"},{"key":"10379_CR193","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2017.03.034","volume":"397","author":"K Takayama","year":"2017","unstructured":"Takayama, K., et al. (2017). Inhibition of the RANK\/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer. Cancer Letters, 397, 103\u2013110. https:\/\/doi.org\/10.1016\/j.canlet.2017.03.034","journal-title":"Cancer Letters"},{"key":"10379_CR194","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1158\/1535-7163.MCT-08-0046","volume":"7","author":"RE Miller","year":"2008","unstructured":"Miller, R. E., et al. (2008). RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Molecular Cancer Therapeutics, 7, 2160\u20132169. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0046","journal-title":"Molecular Cancer Therapeutics"},{"key":"10379_CR195","doi-asserted-by":"publisher","unstructured":"Sturge, J., Caley, M. P., & Waxman, J. (2011). Bone metastasis in prostate cancer: emerging therapeutic strategies. Nature Reviews Clinical Oncology, 8, 357\u2013368. https:\/\/doi.org\/10.1038\/nrclinonc.2011.67","DOI":"10.1038\/nrclinonc.2011.67"},{"key":"10379_CR196","doi-asserted-by":"publisher","unstructured":"Siddiqui, J. A., et al. (2022). GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation. Bone Research, 10, 6. https:\/\/doi.org\/10.1038\/s41413-021-00178-6","DOI":"10.1038\/s41413-021-00178-6"},{"key":"10379_CR197","doi-asserted-by":"publisher","unstructured":"Wu, J. B., et al. (2017). MAOA-dependent activation of Shh-IL6-RANKL signaling network promotes prostate cancer metastasis by engaging tumor-stromal cell interactions. Cancer Cell, 31, 368\u2013382. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.003","DOI":"10.1016\/j.ccell.2017.02.003"},{"key":"10379_CR198","doi-asserted-by":"publisher","unstructured":"Sun, Y., et al. (2021). Macrophage-osteoclast associations: Origin, polarization, and subgroups. Frontiers in Immunology, 12, 2021.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2021.778078","DOI":"10.3389\/fimmu.2021.778078"},{"key":"10379_CR199","doi-asserted-by":"publisher","unstructured":"Yu, Y., et al. (2024). Akkermansia muciniphila metabolite inosine inhibits castration resistance in prostate cancer. Microorganisms, 12,\u00a01653. https:\/\/doi.org\/10.3390\/microorganisms12081653","DOI":"10.3390\/microorganisms12081653"},{"key":"10379_CR200","doi-asserted-by":"publisher","unstructured":"Kim, J. H., et al. (2025). Association of intratumoral microbiota modulation with prostate cancer progression: A microbiome analysis of prostatic tissue. Biomedicines, 13,\u00a01929. https:\/\/doi.org\/10.3390\/biomedicines13081929","DOI":"10.3390\/biomedicines13081929"},{"key":"10379_CR201","doi-asserted-by":"publisher","unstructured":"Cavarretta, I., et al.  (2017). The microbiome of the prostate tumor microenvironment. European Urology 72, 625\u2013631. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.029","DOI":"10.1016\/j.eururo.2017.03.029"},{"key":"10379_CR202","doi-asserted-by":"publisher","unstructured":"Laplane, L., & Maley, C. C. (2024). The evolutionary theory of cancer: Challenges and potential solutions. Nature Reviews Cancer, 24, 718\u2013733. https:\/\/doi.org\/10.1038\/s41568-024-00734-2","DOI":"10.1038\/s41568-024-00734-2"},{"key":"10379_CR203","doi-asserted-by":"publisher","unstructured":"Vendramin, R., Litchfield, K., & Swanton, C. (2021). Cancer evolution: Darwin and beyond. The EMBO Journal, 40,\u00a0EMBJ2021108389. https:\/\/doi.org\/10.15252\/embj.2021108389","DOI":"10.15252\/embj.2021108389"},{"key":"10379_CR204","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ymthe.2022.08.019","volume":"31","author":"BN Smith","year":"2023","unstructured":"Smith, B. N., et al. (2023). Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit. Molecular Therapy, 31, 78\u201389.","journal-title":"Molecular Therapy"},{"key":"10379_CR205","doi-asserted-by":"publisher","first-page":"8488","DOI":"10.7150\/thno.114534","volume":"15","author":"J Chen","year":"2025","unstructured":"Chen, J., et al. (2025). PTEN restoration and CXCR2 depletion synergistically enhance the effect of enzalutamide and inhibit bone metastatic CRPC. Theranostics, 15, 8488\u20138508. https:\/\/doi.org\/10.7150\/thno.114534","journal-title":"Theranostics"},{"key":"10379_CR206","doi-asserted-by":"publisher","unstructured":"Zhang, J., et al. (2022). A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer. Cancers, 14,\u00a05225. https:\/\/doi.org\/10.3390\/cancers14215225","DOI":"10.3390\/cancers14215225"},{"key":"10379_CR207","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-020-0411-1","volume":"17","author":"RA Gatenby","year":"2020","unstructured":"Gatenby, R. A., & Brown, J. S. (2020). Integrating evolutionary dynamics into cancer therapy. Nature Reviews Clinical Oncology, 17, 675\u2013686. https:\/\/doi.org\/10.1038\/s41571-020-0411-1","journal-title":"Nature Reviews Clinical Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10379-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10379-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10379-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:31:51Z","timestamp":1789569111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10379-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":207,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10379"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10379-2","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"69"}}